Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRaG-1 in advanced solid malignancies
NCT07002502Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Soochow University
- Start
- Jun 2025
- Primary completion
- May 2026
- Modality
- Cytokines & Interferons, Monoclonal Antibodies
01
Overview
A Phase 2 trial of pembrolizumab + sargramostim in solid tumor, sponsored by The Second Affiliated Hospital of Soochow University. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
pembrolizumab + sargramostim
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07002502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07002502.